XERS Stock Analysis: Why Xeris Pharmaceuticals Inc Scored 33% in Stock Value Finder

Xeris Pharmaceuticals Inc (XERS): A Detailed Educational Stock Research Review

Overview of Xeris Pharmaceuticals Inc (XERS)

This is an educational stock research article from StockValueFinder.com about Xeris Pharmaceuticals Inc (XERS), a healthcare company in the drug manufacturers – specialty and generic industry. The purpose of this review is to help readers understand how to evaluate key financial metrics when analyzing stocks. We will examine XERS using the StockValueFinder scoring system, which assesses earnings consistency, capital efficiency, financial safety, valuation discipline, and trend timing.

Xeris Pharmaceuticals Inc is a specialty pharmaceutical company focused on developing and commercializing innovative therapies. While we do not evaluate specific products or pipeline potential in this financial review, we will analyze the company's financial health using objective, number-driven metrics. At the time of this review, XERS has a StockValueFinder score of 33%, resulting in an "AVOID" rating. The recent stock price is $10.20.

Why the StockValueFinder Score Matters

The StockValueFinder score is a composite measure designed to help investors identify high-quality stocks based on fundamental and technical discipline. The score ranges from 0% to 100%, with higher scores indicating stronger financial health and more attractive valuation. A score of 33% for XERS suggests that the company has significant financial weaknesses that may pose risks for investors.

Scores are calculated based on five key tests

1. **EPS strength and consistency** – Measures earnings quality and predictability. 2. **ROIC (Return on Invested Capital)** – Evaluates how efficiently the company uses capital to generate profits. 3. **Interest coverage** – Assesses the company's ability to meet interest obligations. 4. **Debt payback** – Determines how quickly the company can repay its debt. 5. **P/E ratio** – Evaluates whether the stock is trading at a reasonable valuation.

Each test is scored as either "Pass" or "Fail," and the overall score reflects the percentage of tests passed. In the case of XERS, only one of the five tests passed, resulting in a 33% score and an "AVOID" rating. This does not mean the stock will necessarily decline, but it does indicate that the company has not met the financial discipline criteria that StockValueFinder prioritizes.

EPS Strength and Consistency

What EPS Strength Measures

Earnings per share (EPS) is a critical measure of a company's profitability. It represents the portion of a company's profit allocated to each outstanding share of common stock. EPS strength and consistency are important because they indicate whether a company can generate reliable earnings over time. Companies with stable or growing EPS are generally considered more predictable and less risky than those with volatile or declining earnings.

How StockValueFinder Evaluates EPS

StockValueFinder evaluates EPS strength by analyzing historical earnings trends, including consistency, growth, and quality. While the exact EPS values for XERS are not supplied, the system recorded a "Did not pass" result for this test. This suggests that XERS has not demonstrated the level of earnings consistency that StockValueFinder considers attractive.

What a Strong EPS Looks Like

A strong EPS profile typically includes

– **Consistent growth**: Earnings that increase steadily over time, such as 5-10% annual growth. – **Low volatility**: Minimal fluctuations in earnings from quarter to quarter or year to year. – **Positive earnings**: No prolonged periods of losses.

For example, a company with EPS of $1.00, $1.10, $1.20, and $1.30 over four consecutive years demonstrates consistent growth and would likely pass the EPS test. In contrast, a company with EPS of $0.50, -$0.20, $0.80, and -$0.10 would fail due to volatility and losses.

Why XERS Failed the EPS Test

Since the exact EPS values for XERS are not provided, we cannot analyze specific trends. However, the "Did not pass" result indicates that the company's earnings history did not meet the criteria for consistency or quality. This could be due to factors such as: – Frequent losses or negative EPS. – Highly volatile earnings with large swings. – Inconsistent growth patterns.

Investors should be cautious when evaluating companies with weak EPS profiles, as unreliable earnings can lead to unpredictable stock performance.

ROIC and Capital Efficiency

What ROIC Measures

Return on Invested Capital (ROIC) is a measure of how efficiently a company uses its capital to generate profits. It is calculated as: **ROIC = Net Operating Profit After Taxes (NOPAT) / Invested Capital**

ROIC is a critical metric because it shows whether a company is generating sufficient returns on the capital it deploys. Companies with high ROIC are often better at allocating resources and creating shareholder value.

How StockValueFinder Evaluates ROIC

StockValueFinder generally prefers companies with an ROIC of **10% or higher**. This threshold indicates that the company is generating strong returns relative to its capital base. For context, an ROIC of 15% is typically considered excellent, while an ROIC below 5% may signal inefficiency or weak competitive positioning.

XERS's ROIC: 1.08%

Xeris Pharmaceuticals Inc has an ROIC of **1.08%**. This is significantly below the 10% threshold that StockValueFinder considers attractive. To put this into perspective: – A company with an ROIC of 15% is generating $15 in profit for every $100 of invested capital. – A company with an ROIC of 1.08%, like XERS, is generating only $1.08 in profit for every $100 of invested capital.

This low ROIC suggests that XERS is not efficiently using its capital to generate profits. It may be struggling with high costs, low margins, or competitive pressures that limit its ability to generate strong returns.

Why XERS Failed the ROIC Test

Given that StockValueFinder prefers an ROIC of 10% or higher, XERS's ROIC of 1.08% falls well short of this standard. This is a significant weakness, as it indicates that the company is not generating sufficient returns on its invested capital. Investors should be cautious when evaluating companies with low ROIC, as they may face challenges in sustaining profitability or growing shareholder value.

Interest Coverage and Financial Safety

What Interest Coverage Measures

Interest coverage is a measure of a company's ability to meet its interest obligations on outstanding debt. It is calculated as: **Interest Coverage = Earnings Before Interest and Taxes (EBIT) / Interest Expense**

This metric is important because it indicates whether a company can comfortably service its debt. Companies with low interest coverage may struggle to meet their debt obligations, which can lead to financial distress or bankruptcy.

How StockValueFinder Evaluates Interest Coverage

StockValueFinder prefers companies with an interest coverage ratio of **6 or higher**. This threshold indicates that the company is generating sufficient earnings to cover its interest expenses multiple times over. For example: – A company with an interest coverage ratio of 8x is generating $8 in EBIT for every $1 of interest expense, which is considered healthy. – A company with an interest coverage ratio of 2x is generating only $2 in EBIT for every $1 of interest expense, which may be risky.

XERS's Interest Coverage: Did Not Pass

The system recorded a "Did not pass" result for XERS's interest coverage test. While the exact interest coverage ratio is not supplied, this result suggests that XERS's interest coverage is below the preferred threshold of 6. This is a red flag, as it indicates that the company may be struggling to generate sufficient earnings to cover its interest obligations.

Why XERS Failed the Interest Coverage Test

Since the exact interest coverage ratio is not provided, we cannot analyze the specific level of risk. However, the "Did not pass" result indicates that XERS's interest coverage is likely below 6, which is considered weak. Companies with low interest coverage may face challenges in servicing their debt, particularly if earnings decline or interest rates rise. Investors should be cautious when evaluating companies with weak interest coverage, as they may be at higher risk of financial distress.

Debt Payback and Balance Sheet Discipline

What Debt Payback Measures

Debt payback measures how quickly a company can repay its total debt using its operating cash flow. It is calculated as: **Debt Payback Years = Total Debt / Annual Operating Cash Flow**

This metric is important because it indicates the company's ability to manage its debt load. Companies with shorter debt payback periods are generally considered financially healthier, as they can repay their debt more quickly and reduce financial risk.

How StockValueFinder Evaluates Debt Payback

StockValueFinder prefers companies with a debt payback period of **3 years or less**. This threshold indicates that the company can repay its debt relatively quickly using its operating cash flow. For example: – A company with a debt payback period of 1.5 years is generating sufficient cash flow to repay its debt in a short time frame, which is considered strong. – A company with a debt payback period of 7 years may struggle to repay its debt quickly, which is considered weak.

XERS's Debt Payback: 7.89 Years

Xeris Pharmaceuticals Inc has a debt payback period of **7.89 years**. This is significantly longer than the preferred threshold of 3 years. To put this into perspective: – A company with $100 million in debt and $50 million in annual operating cash flow would have a debt payback period of 2 years ($100 million / $50 million). – XERS, with a debt payback period of 7.89 years, would require nearly 8 years to repay its debt using its operating cash flow.

This long debt payback period suggests that XERS may be carrying a heavy debt load relative to its cash flow generation. This is a significant weakness, as it indicates that the company may face challenges in repaying its debt in a timely manner.

Why XERS Failed the Debt Payback Test

Given that StockValueFinder prefers a debt payback period of 3 years or less, XERS's debt payback period of 7.89 years falls well short of this standard. This is a red flag, as it indicates that the company may be overleveraged and could struggle to repay its debt. Investors should be cautious when evaluating companies with long debt payback periods, as they may face higher financial risk.

P/E Ratio and Valuation Discipline

What P/E Ratio Measures

The price-to-earnings (P/E) ratio is a measure of a company's valuation relative to its earnings. It is calculated as: **P/E Ratio = Stock Price / Earnings Per Share (EPS)**

The P/E ratio is important because it helps investors determine whether a stock is trading at a reasonable price relative to its earnings. A low P/E ratio may indicate that a stock is undervalued, while a high P/E ratio may suggest that it is overvalued.

How StockValueFinder Evaluates P/E Ratio

StockValueFinder prefers companies with a P/E ratio of **15 or lower**. This threshold is designed to identify stocks that are trading at reasonable valuations relative to their earnings. For example: – A company with a P/E ratio of 8 is trading at 8 times its earnings, which may be considered attractive if the business quality is sound. – A company with a P/E ratio of 40 is trading at 40 times its earnings, which may be considered expensive unless the company has strong growth prospects.

XERS's P/E Ratio: -1,569.23

Xeris Pharmaceuticals Inc has a P/E ratio of **-1,569.23**. This negative P/E ratio indicates that the company is currently unprofitable, as it is generating negative earnings. While the P/E ratio is not meaningful for unprofitable companies, StockValueFinder's system recorded a "Pass" for this test. This is likely because the system prioritizes valuation discipline, and a negative P/E ratio does not necessarily indicate overvaluation in the same way that a high positive P/E ratio would.

Why XERS Passed the P/E Ratio Test

While XERS's negative P/E ratio is not ideal, the system recorded a "Pass" for this test. This is because the P/E ratio is not a useful metric for unprofitable companies, and the system does not penalize XERS for being unprofitable in this context. However, investors should note that a negative P/E ratio is a significant weakness, as it indicates that the company is not generating profits. This is a red flag that should be considered alongside other financial metrics.

Moving Average Trend and Entry Timing

What Moving Average Trend Measures

The moving average trend is a technical indicator that helps investors identify the direction of a stock's price movement. It is calculated by averaging the stock's price over a specific period (e.g., 50-day or 200-day moving average) and comparing it to the current price. A "Strong Buy Trend" signal indicates that the stock's price is above its moving averages, which may suggest upward momentum.

How StockValueFinder Uses Moving Average Trend

StockValueFinder uses the moving average trend as a timing discipline tool, not as proof that the stock will continue to rise. A "Strong Buy Trend" signal indicates that the stock is in an uptrend based on its moving averages, but this does not guarantee future performance. Investors should use trend signals as one factor in their decision-making process, alongside fundamental analysis.

XERS's Moving Average Trend: Strong Buy Trend

Xeris Pharmaceuticals Inc has a "Strong Buy Trend" signal based on its moving averages. This suggests that the stock's price is currently above its key moving averages, which may indicate upward momentum. However, it is important to note that trend signals are not a guarantee of future performance. Investors should not rely solely on technical trends when evaluating a stock, particularly if the company has weak fundamentals.

Entry Signal and Risk Levels

The system recorded "N/A" for the entry signal, limit buy idea, pullback zone, and risk/trend level. This means that StockValueFinder does not provide specific entry or risk levels for XERS at this time. Investors should use their own judgment when determining whether to buy, hold, or sell the stock, and should consider the company's fundamental weaknesses alongside any technical trends.

Overall Financial Strengths and Weaknesses

Strengths

1. **P/E Ratio Test Passed**: While the P/E ratio is negative, the system did not penalize XERS for this, as the P/E ratio is not a meaningful metric for unprofitable companies. 2. **Strong Buy Trend**: The stock is currently in an uptrend based on its moving averages, which may indicate short-term momentum.

Weaknesses

1. **EPS Strength**: XERS did not pass the EPS test, indicating weak or inconsistent earnings. 2. **ROIC of 1.08%**: The company's ROIC is well below the preferred threshold of 10%, suggesting inefficient use of capital. 3. **Interest Coverage**: XERS did not pass the interest coverage test, indicating potential difficulties in meeting debt obligations. 4. **Debt Payback of 7.89 Years**: The company's debt payback period is significantly longer than the preferred threshold of 3 years, indicating a heavy debt load relative to cash flow. 5. **Negative P/E Ratio**: The company is unprofitable, which is a significant red flag for investors.

Risks and Limitations

Financial Risks

1. **Low ROIC**: XERS's ROIC of 1.08% suggests that the company is not generating sufficient returns on its invested capital. This may limit its ability to grow or create shareholder value. 2. **High Debt**: The company's debt payback period of 7.89 years indicates that it may be overleveraged and could struggle to repay its debt. 3. **Weak Interest Coverage**: The "Did not pass" result for interest coverage suggests that XERS may have difficulty meeting its interest obligations, which could lead to financial distress. 4. **Negative Earnings**: The company's negative P/E ratio indicates that it is unprofitable, which is a significant risk for investors.

Market Risks

1. **Industry Competition**: The drug manufacturers – specialty and generic industry is highly competitive, and XERS may face challenges in maintaining or growing its market share. 2. **Regulatory Risks**: Pharmaceutical companies are subject to strict regulatory oversight, and XERS may face risks related to product approvals, compliance, or legal challenges. 3. **Stock Volatility**: The stock's "Strong Buy Trend" signal indicates upward momentum, but this does not guarantee future performance. Stocks with weak fundamentals can be volatile and may experience sharp declines.

Limitations of This Analysis

1. **Lack of Detailed EPS Data**: The exact EPS values for XERS are not provided, which limits our ability to analyze earnings trends in detail. 2. **No Pipeline or Product Data**: This analysis focuses solely on financial metrics and does not evaluate XERS's product pipeline, competitive positioning, or growth prospects. 3. **No Analyst Estimates or Future Predictions**: This review is based on historical financial data and does not incorporate analyst estimates or future projections. 4. **No Dividend or Shareholder Return Data**: This analysis does not evaluate XERS's dividend policy or shareholder return programs, as the company does not pay a dividend.

Educational Conclusion

This educational review of Xeris Pharmaceuticals Inc (XERS) has analyzed the company's financial health using the StockValueFinder scoring system. With a score of 33% and an "AVOID" rating, XERS has significant financial weaknesses that may pose risks for investors. The company failed four of the five key tests: EPS strength, ROIC, interest coverage, and debt payback. It passed only the P/E ratio test, which is not meaningful given its negative earnings.

Key Takeaways for Investors

1. **EPS Consistency Matters**: Companies with weak or inconsistent earnings may face higher risks. XERS did not pass the EPS test, indicating unreliable earnings. 2. **ROIC Indicates Capital Efficiency**: A low ROIC, like XERS's 1.08%, suggests that the company is not efficiently using its capital to generate profits. 3. **Interest Coverage Reflects Financial Safety**: Companies with weak interest coverage may struggle to meet debt obligations. XERS did not pass this test. 4. **Debt Payback Measures Balance Sheet Health**: A long debt payback period, like XERS's 7.89 years, indicates a heavy debt load relative to cash flow. 5. **P/E Ratio Evaluates Valuation**: While XERS passed this test, its negative P/E ratio is a red flag, as it indicates the company is unprofitable. 6. **Trend Signals Are Not Guarantees**: XERS has a "Strong Buy Trend" signal, but this does not guarantee future performance, especially given its weak fundamentals.

How to Apply This Analysis to Other Stocks

When evaluating other stocks, use these metrics as a framework for assessing financial health: – **EPS Strength**: Look for consistent, growing earnings with low volatility. – **ROIC**: Aim for companies with ROIC of 10% or higher, indicating efficient capital use. – **Interest Coverage**: Prefer companies with interest coverage of 6 or higher for financial safety. – **Debt Payback**: Seek companies with debt payback periods of 3 years or less for balance sheet discipline. – **P/E Ratio**: Consider companies with P/E ratios of 15 or lower for valuation discipline, assuming the business quality is sound. – **Moving Average Trend**: Use trend signals as a timing tool, but prioritize fundamental analysis.

This article is for research and educational purposes only. It is not personal financial advice, investment advice, or a recommendation to buy or sell any security. Always conduct your own research and consult with a financial advisor before making investment decisions.

---

Research links: Yahoo Finance | Seeking Alpha | Finviz | SEC Filings